Skip to contentB
Biogen Inc.
B
BIIBBiogen Inc. Q1 2013 · 10-Q
Revenue$1.42B$1.42B+9.5% vs Q1 2012 Net Income$426.70M$426.70M+41.0% vs Q1 2012 EPS Diluted$1.79$1.79+43.2% vs Q1 2012 Gross Profit$1,281,400,000+10.6% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Biogen Inc. · CIK 875045 · Engraved from SEC EDGAR
Operating Cash Flow$178,939,000−8.1% Free Cash Flowderived$145,650,000+4.0% Margins · derivedGross margin90.6%+0.9 pt vs Q1 2012
Operating margin36.1%+7.5 pt vs Q1 2012
Net margin30.2%+6.7 pt vs Q1 2012
ended Mar 31, 2013 · filed Apr 25, 2013 · 25 d after period end